# Thermo Fisher Scientific (TMO) — InvestMoat Analysis _Last analyzed: August 13, 2026_ _Asset class: equity · Canonical page: https://investmoat.com/stocks/tmo_ ## Scores | Dimension | Score (0–100) | | --- | --- | | Moat durability | 67 | | Growth trajectory | 68 | | Valuation | 68 | | **Composite** | **67** | Scores are computed deterministically from this asset’s data by the InvestMoat formula (see https://investmoat.com/llms.txt for methodology). Scores are not directly comparable across asset classes. ## Key stats - **Ticker:** TMO - **Market Cap:** ~$226B ## Moat Lab-tools and bioprocessing razor-blade with FDA-validated workflows that make switching prohibitively expensive in regulated pharma manufacturing. ### The FDA-Validated Workflow Moat Thermo Fisher's moat is the **regulatory cost of switching** — once a TMO instrument is validated for cGMP production, swapping it requires re-running the full regulatory submission: - **FDA-Validated Switching Cost:** When a pharma customer validates a TMO instrument or reagent for cGMP production, replacing it requires full process revalidation — months of work, $millions in cost, and tapeout-equivalent regulatory risk. This is the dominant moat for the bioproduction segment. - **Razor-Blade Economics:** TMO sells the instrument once, then captures recurring consumables, reagents, and service revenue at high margins for the instrument's 8-15 year life. Roughly 80% of revenue is recurring consumables/service — the installed base compounds even when capex slows. - **M&A Compounding Engine:** TMO has a 30-year track record of acquiring scientific tooling companies (Life Tech, Patheon, PPD, Thermo Electron, Olink, Clario) and bolting them onto the global commercial channel. The bolt-on model adds 2-3pp of growth above organic in most years. **Moat verdict:** Thermo Fisher is a moderate AI beneficiary. The strongest moats — regulatory lock-in, transaction embedding, and the bundling razor-blade — are AI-neutral or AI-strengthened (AI assists method development without disrupting the regulatory cost-of-switching). The AI-vulnerable categories (learnedInterfaces, businessLogic, talentScarcity) are merely intact rather than destroyed because regulated workflows protect them. Sits in the healthcare peer range (80-90) alongside ISRG/LLY, just below the financial-data oligopoly tier. ### Top competitors - **Danaher (DHR):** Bioprocessing and life-science tools. - **Agilent Technologies (A):** Analytical instruments. - **Merck KGaA (MRK.DE):** Life-science consumables. ## Growth Q2 2026 showed a cleaner recovery than Q1: revenue grew 10% to $11.99B, organic revenue grew 5% (Q1: revenue +6% to $11.01B, organic +1%), adjusted EPS rose 13% to $6.03, and adjusted operating margin expanded 90 bps to 22.8% after slipping 10 bps to 21.8% in Q1. Management raised FY26 guidance to $47.4-48.1B revenue — +6-8% on FY2025's $44.56B, including acquired revenue — and $24.93-25.33 adjusted EPS, while now expecting organic growth at the upper end of the 3-4% range. The pending microbiology divestiture trims 2026 revenue by about $200M and adjusted EPS by $0.05, so the guidance raise is higher quality than the headline suggests. - **Revenue CAGR estimate:** 5-8% - **Primary type:** both - **Margin trend:** expanding - **Key risk (moderate):** If pharma/biotech bioproduction demand rolls over again in 2H 2026 and organic growth falls back below 3% after the Q2 acceleration, the raised EPS guide becomes dependent on cost actions and M&A rather than the core recurring-revenue engine. - **Drivers:** - Life Sciences Solutions — Q2 2026 segment revenue +13% reported, +3% organic (Q2 call); bioproduction recovery against Q1's +1% companywide organic print (accelerating) - Lab Products & Biopharma Services — Q2 2026 revenue beat helped by stronger customer activity; FY organic outlook now upper end of 3-4% (accelerating) - M&A Bolt-Ons (Clario) — Clario adds acquired revenue to the reported line while the pending microbiology divestiture removes ~$200M of 2026 revenue (stable) - **Score derivation:** Base 66.3 (5-8% revenue CAGR, midpoint 6.5%) + 2.7 trajectory (Life Sciences Solutions and Lab Products & Biopharma Services accelerating as organic growth went +1% → +5%; Clario bolt-on stable) + 4 expanding margin (adjusted operating margin 21.8% in Q1, −10bps, then 22.8% in Q2, +90bps) − 5 moderate pharma/biotech funding risk = 68 ## Valuation At $603.01, TMO is now much closer to fair value: about 89% of the way from the rebuilt bear case ($470) to base case ($620). Q2 supports lifting the ladder because organic growth improved to 5%, margin expanded, and FY26 EPS guidance moved up despite the microbiology divestiture. The valuation score falls because the stock moved faster than the guide: upside now requires sustained 4%+ organic growth and bioprocessing recovery, not just a return to normal from the 2025 trough. | Multiple | Value | Note | | --- | --- | --- | | Trailing P/E (GAAP) | ~25× | TTM GAAP EPS depressed by acquisition charges | | Forward P/E (NTM) | ~24× | $25.13 midpoint of raised 2026 adjusted EPS guide | | PEG Ratio | ~2.7× | fwd P/E ÷ ~9% EPS CAGR | | Price / Sales (NTM) | ~4.7× | $47.75B midpoint of raised 2026 revenue guide | | Price / FCF | ~30× | FCF conversion ~80% of net income | Forward P/E has re-rated from a discount to roughly the middle of the healthcare-tools quality range. That is justified by Q2's 5% organic growth and 22.8% adjusted margin, but the easy valuation gap has closed. The microbiology divestiture sharpens the portfolio but is modestly dilutive, so the next leg depends on recurring consumables and bioprocessing demand staying firm. _(as of August 2026)_ ## Price scenarios ### Bear — $470 Bioprocessing recovery stalls into 2027, Q2 organic strength proves temporary, tariff and funding headwinds return, and the multiple compresses toward 18-19× forward earnings. - Pharma/biotech capex remains soft, and organic growth falls back below 3% after the Q2 2026 acceleration - Tariff, FX, and microbiology separation costs offset productivity, pulling adjusted operating margin back toward 21.5% - Forward P/E re-rates to ~18-19× on a $25 EPS base as the slow-organic narrative becomes structural ### Base — $620 FY26 guide hits the raised midpoint ($47.75B revenue / $25.13 EPS), organic growth holds near 4% in 2H, and the multiple holds around 24-25× forward earnings. - Organic growth remains near the upper end of the 3-4% FY guide after Q2's 5% print, confirming that customer activity has strengthened - Clario integration contributes to 2027 EPS while the microbiology divestiture is absorbed without disrupting channel relationships - Adjusted operating margin stays above 22.5% as productivity offsets tariffs, FX, and divestiture dilution ### Bull — $770 Bioprocessing fully recovers to sustained mid-single-digit organic growth, M&A returns to accretive bolt-ons, and the multiple expands toward TMO's premium historical range. - GLP-1 manufacturing capacity buildouts and biologics pipeline drive bioproduction back to high-single-digit organic growth - Accretive M&A resumes in clinical trials, diagnostics, or specialty consumables after the microbiology divestiture closes - Forward P/E re-rates to 27-28× as the compounder narrative reasserts and 2027 EPS power approaches $28 --- InvestMoat is a research and education framework. Nothing here is financial advice. Past performance does not guarantee future results.